---
title: "management of Pathologic stage IIIA (N2) to IIIB disease of NSCLC"
slug: "management-of-pathologic-stage-iiia-n-to-iiib-disease-of-nsclc"
date: "2023-11-09"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[NSCLC]]

# management of Pathologic stage IIIA (N2) to IIIB disease of NSCLC

- Surgery, rad onc, & med onc consults mandatory for multimodality tx. Sequence of surgery, RT, & chemo varies
- Induction: If resectable, neoadj chemo is best response followed by resection + PORT. Neoadj chemoRT does not improve OS
- Concurrent ChemoRT: If unresectable (multiple +N2 LN >3 cm), definitive concurrent chemoRT (JCO 1999;17:2692), regimens: CIS/peme, CIS/vinblastine, CIS/etoposide, carbo/paclitaxel
- Pancoast tumor: ChemoRT (CIS/etoposide + 45 Gy) followed by surgery (T3N0-1) improves resectability (SWOG 9416, JCO 2007;25:313). If unresectable (T4N0-1), chemoRT
- Adj. checkpoint inhibitor in IIIB unresectable: â†‘ OS w/ durvalumab for 1 y after response to plat doublet w/ definitive RT (NEJM 2018;379:2342)
